BL Pharmtech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
BL Pharmtech supplies health-functional foods, such as hemp seed oil and other dietary supplements, alongside a self-collection diagnostic device that allows women to test for cervical cancer and sexually transmitted diseases at home, without visiting a clinic.
Its consumer health products reach end-users through home-shopping channels and online retail platforms, while its in-vitro diagnostic device targets individual consumers directly. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three distinct divisions: consumer health foods, in-vitro diagnostic devices, and anti-cancer drug development.
Summary is AI-generated and may contain errors · figures from DART filings
BL Pharmtech is the largest shareholder of an affiliated company, BL Melanis, through which it conducts its anti-cancer drug pipeline development.
BL Pharmtech in five facts
What does BL Pharmtech do?
BL Pharmtech supplies health-functional foods, such as hemp seed oil and other dietary supplements, alongside a self-collection diagnostic device that allows women to test for cervical cancer and sexually transmitted diseases at home, without visiting a clinic.
Where is BL Pharmtech listed and in which sector?
BL Pharmtech (Korean name: 비엘팜텍) trades under KRX code 065170 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Staples sector, Staples Retail.
How large is BL Pharmtech?
Its market capitalisation was US$41.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were BL Pharmtech's latest annual revenue and operating profit?
For fiscal year 2025, BL Pharmtech reported revenue of US$4.9M, an operating loss of US$2.1M and a net loss of US$12.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 26.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Decision to acquire shares/equity in another company
BL Pharmtech updated the disclosed terms of an acquisition, now worth US$777K.
M&A · Sep 10 · 2 versions - [Amended] Material event report (convertible bonds)
BL Pharmtech updated the terms of convertible bonds to raise US$687K, about 1.7% of its market value.
Capital raise · Jun 15 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
BL Pharmtech reported consolidated results for FY2025: revenue of US$4.54M (−26.12% year on year), an operating loss of US$1.86M and a net loss of US$5.8M.
Earnings · Feb 27